Cepham has announced that it will prioritize bridging the gender gap in health research and innovation, and focus on women’s health solutions. The company has outlined a plan which includes increasing funding toward underrepresented areas, inclusive research designs, and communicating to raise awareness and support for women’s health initiatives, such as Women in Nutraceuticals (WIN).  
 
“It typically takes 15-20 years for research discoveries to be adopted into clinical practice. This delay is a significant barrier to implementing new findings in women’s health,” said Anand Swaroop, founder and president of Cepham and director at large for WIN. “By closing these research gender gaps, we can ensure that women’s health issues receive the attention and resources needed for better health outcomes.”
 
Swaroop said that immediate policy interventions are needed to prioritize and adequately fund women’s health research.
 
Cepham’s has studied its fenugreek seed extract, Furocyst, in its ability to support insulin sensitivity and reduce ovarian cysts. It’s been clinically studied in 520 patients and is evidenced to improve glucose metabolism and hormonal balance in polycystic ovary syndrome (PCOS).
 
Cepham’s SheVari4 is an ayurvedic herb formulation designed to address menopausal symptoms, including focus and mood issues, by supporting hormonal balance.
 
Cepham will showcase both of these ingredients, and other woman-targeted products, at SupplySide West, booth 3051, in Las Vegas. The company will also participate in the Women’s Wellness Walk on Oct. 30 and 31.